dupilumab   Click here for help

GtoPdb Ligand ID: 7574

Synonyms: Dupixent® | REGN668 | SAR231893
Approved drug Immunopharmacology Ligand
dupilumab is an approved drug (EMA & FDA (2017))
Compound class: Antibody
Comment: Dupilumab is fully human monoclonal antibody against the α subunit of the IL4 receptor.
Peptide sequences for this antibody are available from its IMGT/mAb-db record. Dupilumab was produced using Regeneron's genetically engineered VelocImmune® mice which have humanized immunoglobulin gene loci and produce human:mouse hybrid antibodies that can rapidly be converted to fully human antibodies [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Immunopharmacology Comments
Dupilumab inhibits IL-4 and IL-13 (two cytokines that promote inflammation and which are elevated in patients with atopic dermatitis and asthma) binding to the shared receptor alpha subunit, interleukin-4 receptor subunit α. This action prevents IL-4 and IL-13 from activating downstream pro-inflammatory pathways and relieves the symptoms of the targeted diseases.
Immunopharmacology Disease
Disease X-Refs Comment References
Atopic dermatitis Disease Ontology: DOID:3310
OMIM: 603165
 Dupilumab is approved to treat atopic dermatitis (eczema).
Asthma Disease Ontology: DOID:2841
OMIM: 600807
 Approved drug for asthma (FDA approval in October 2018).